Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.47 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.47 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.47 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.47 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.47 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.47 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.47 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11205766 | 1.00 | ALDH1A1 (0.62) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL10389939 | 1.00 | ALDH1A1 (0.62) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL28676692 | 0.92 | GAA (0.61) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL1884341 | 0.85 | GAA (0.73) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL6376702 | 0.85 | GAA (0.73) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL5604987 | 0.85 | GAA (0.73) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL11207120 | 0.82 | ALDH1A1 (0.65) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL673127 | 0.82 | ALDH1A1 (0.67) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL3408275 | 0.82 | ALDH1A1 (0.65) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL3246564 | 0.81 | MEN1 (0.47) | ALDH1A1GAAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| CN-101115715-A | Pyrrolidine derivatives for the treatment of diseases associated with renin activity | NOVARTIS AG (CH) | 2008-01-30 | — | — | CN | disclosed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | ALDH1A1 494/4885GAA 84/4885MEN1 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.